| Literature DB >> 26561011 |
Dablu Lal Gupta1, Predeep Kumar Nagar2, Vineet Kumar Kamal3, Sanjeev Bhoi4, D N Rao5.
Abstract
INTRODUCTION: The susceptibility to adverse outcome from critical injury (occurrence of sepsis, septic shock, organ dysfunction/failure, and mortality) varies dramatically due to different degrees of inflammatory response. We assessed the relationship of the genotype distribution of various cytokine gene polymorphisms (CGP) with regard to the development of sepsis, organ dysfunction or mortality in severely injured patients.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26561011 PMCID: PMC4642631 DOI: 10.1186/s13049-015-0174-3
Source DB: PubMed Journal: Scand J Trauma Resusc Emerg Med ISSN: 1757-7241 Impact factor: 2.953
Fig. 1A representative 2 % agarose gel diagram of a battery of pro and anti-inflammatory cytokine gene variants. Each of the primer mixes contained a non-allelic internal control primer pair, which amplified either a part of the β-globin gene (440 bp amplicon) in upper row or a part of the C-reactive protein gene (CRP) at 89 bp in lower row
Clinical characteristics of trauma victim with hemorrhagic shock patients (n = 114)
| Number | Percent | |
|---|---|---|
| Age (yrs), mean ± sd | 34.3 ± 14.5 | |
| (16–60) | ||
| Male/Female | 98/16 | |
| No of body region injured | ||
| Two | 52 | 45.6 |
| Three | 35 | 30.7 |
| Four | 27 | 23.6 |
| ISS (Injury severity scale) | 18.71 ± 8.48 | |
| Shock Index (S.I) | 1.17 ± 0.51 | |
| Organ dysfunction | ||
| One | 35 | 30.7 |
| Two | 27 | 23.6 |
| Three or above | 12 | 10.5 |
| Cause of trauma | ||
| Traffic accident | 82 | 71.9 |
| Free fall from a height | 17 | 14.9 |
| Heavy weight blunts Injury | 15 | 13.1 |
| Survival | 77 | 67.5 |
| Death | 37 | 32.5 |
Clinical characteristics of survivors and non-survivors patients
| Survivors | Non-survivors |
| |
|---|---|---|---|
| Patients |
|
| |
| Sex (M/F) | 65/12 | 33/4 | 0.35 |
| Age (yrs) | 33.7 ± 14.4 | 35.6 ± 14.8 | 0.26 |
| ISS | 15.2 ± 6.4 | 26.1 ± 7.3 | 0.02 |
| S.I | 1.14 ± 0.35 | 1.2 ± 0.74 | 0.43 |
| SOFA-7 | 3.5 ± 1.57 | 7.2 ± 2.34 | 0.001 |
| SOFA-14 | 5.2 ± 1.7 | 10.3 ± 1.15 | 0.001 |
M/F represents males and females. ISS and S.I represent Injury severity scale and Shock Index
SOFA-7 and SOFA-14 represents the sequential organ failure assessment score on day 7 and 14
Clinical characteristics of patients with sepsis and non-sepsis
| Sepsis | Non-sepsis |
| |
|---|---|---|---|
| Patients |
|
| |
| Sex (M/F) | 18/7 | 72/17 | 0.02 |
| Age (yrs) | 37.5 ± 16.1 | 33.4 ± 13.9 | 0.21 |
| ISS | 21.2 ± 6.8 | 18 ± 8.8 | 0.05 |
| S.I | 1.2 ± 0.44 | 1.16 ± 0.53 | 0.5 |
| SOFA-7 | 5.28 ± 1.96 | 3.78 ± 2.34 | 0.006 |
| SOFA-14 | 7.86 ± 2.18 | 4.77 ± 2.31 | 0.0001 |
| Mortality | |||
| n (%) | 16(64) | 21(29.5) | 0.001 |
M/F represents males and females. ISS and S.I represent Injury severity scale and Shock Index
SOFA-7 and SOFA-14 represents the sequential organ failure assessment score on day 7 and 14
Genotypic and allelic frequency distribution in patients with sepsis and non-sepsis
| Cytokine gene polymorphism | Genotype | Non-sepsis | Sepsis |
| OR (95 % CI) |
|---|---|---|---|---|---|
| f (%) | f(%) | ||||
|
|
| ||||
| IL-1α(−889) | CC | 45(50.56) | 21(84) | 1 | |
| TC | 32(35.96) | 3(12) | 0.01 | 0.20(0.05–0.73) | |
| TT | 12(13.48) | 1(4) | 0.17(0.02–1.4) | ||
| C | 122(68.5) | 45(90) | 1 | ||
| T | 56(31.5) | 5(10) | 0.002 | 0.24(0.07-0.6) | |
| TNF-α(−308) | AA | 3(3.3) | 2(8) | 1 | |
| GA | 17(19.1) | 1(4) | 0.09 | 0.08(0.05–1.3) | |
| GG | 69(77.6) | 22(88) | 0.47(0.07–3.0) | ||
| A | 23(13) | 5(10) | 1 | ||
| G | 155(87) | 45(90) | 0.57 | 1.3(0.46–4.7) | |
| TNF-α(−238) | GG | 78(87.7) | 19(76) | 1 | |
| GA | 10(11.2) | 4(16) | 0.13 | 0.2 (0.13–2.8) | |
| AA | 1(1.1) | 2(8) | 0.12(0.01–1.4) | ||
| G | 166(93.2) | 42(84) | 0.04 | 1 | |
| A | 12(6.8) | 8(16) | 2.6(0.87–7.5) | ||
| IL-4(−1098) | TT | 66(74.1) | 12(48) | 1 | |
| TG | 21(23.6) | 9(36) | 0.006 | 2.3(0.87–6.3) | |
| GG | 2(2.3) | 4(16) | 11(1.8–66.9) | ||
| T | 153(86) | 33(82) | 0.001 | 1 | |
| G | 25(14) | 17(18) | 3.1(1.4–6.8) | ||
| IL-10(−1082) | GG | 5(5.7) | 4(16) | 1 | |
| GA | 33(37) | 2(8) | 0.01 | 0.07 (0.01–0.52) | |
| AA | 51(57.3) | 19(76) | 0.46 (0.11–1.9) | ||
| G | 30(16.9) | 10(20) | 0.60 | 1 | |
| A | 148(83.1) | 40(80) | 0.8(0.34–2.0) | ||
| IL-10(−819) | CC | 63(70.7) | 16(64) | 1 | |
| CT | 22(24.7) | 6(24) | 0.39 | 0.10 (0.03–3.0) | |
| TT | 4(4.6) | 3(12) | 0.65 (0.14–2.9) | ||
| C | 148(83.1) | 12(76) | 0.001 | 1 | |
| T | 30(16.9) | 31(24) | 12.7(5.5–30.1) |
Distribution of genotypes in non-sepsis and sepsis patients using multivariate logistic regression analysis
| Cytokine gene polymorphism | Genotype | Non-sepsis | Sepsis | Unadjusted odds ratio | Adjusted odds ratio | ||
|---|---|---|---|---|---|---|---|
| f (%) | f (%) | OR (95 % C.I) |
| OR (95 % C.I) |
| ||
|
|
| ||||||
| IL-α(−889) | CC | 45(50.56) | 21(84) | 1 | 1 | ||
| TC | 32(35.96) | 3(12) | 0.20(0.05–0.73) | 0.01 | 0.21(0.05–0.79) | 0.02 | |
| TT | 12(13.48) | 1(4) | 0.17(0.02–1.4) | 0.10 | 0.25(0.02–2.1) | 0.20 | |
| TNF-α(−238) | GG | 78(87.7) | 19(76) | 1 | 1 | ||
| GA | 10(11.2) | 4(16) | 0.2 (0.13–2.8) | 0.2 | 0.19(0.01–3.1) | 0.2 | |
| AA | 1(1.1) | 2(8) | 0.12(0.01–1.4) | 0.09 | 0.09(0.007–1.3) | 0.08 | |
| TNF-α(−308 | AA | 3(3.3) | 2(8) | 1 | 1 | ||
| GA | 17(19.1) | 1(4) | 0.08(0.05–1.3) | 0.07 | 0.10(0.006–1.6) | 0.10 | |
| GG | 69(77.6) | 22(88) | 0.47(0.07–3.0) | 0.43 | 0.64(0.09–4.6) | 0.66 | |
| IL-4(−1098) | TT | 66(74.1) | 12(48) | 1 | 1 | ||
| TG | 21(23.6) | 9(36) | 2.3(0.87–6.3) | 0.09 | 1.8(0.47–7.5) | 0.36 | |
| GG | 2(2.3) | 4(16) | 11(1.8–66.9) | 0.009 | 6.1(0.58–64) | 0.12 | |
| IL-10(−1082) | GG | 5(5.7) | 4(16) | 1 | 1 | ||
| GA | 33(37) | 2(8) | 0.07(0.01–0.52) | 0.01 | 0.36(0.03–3.5) | 0.38 | |
| AA | 51(57.3) | 19(76) | 0.65(0.11–1.9) | 0.29 | 1.9(0.33–11.5) | 0.45 | |
n (%) = number of subjects (expressed as percentage),OR = odds ratio, CI = class intervals
Adjusted odds ratio for ISS, SOFA score and gender
Distribution of haplotype in patient with sepsis and non-sepsis
| Cytokine gene | Haplotypes | Distribution of haplotype in patients with sepsis and non-sepsis | |||
|---|---|---|---|---|---|
| Polymorphism | Sepsis patients | Non-sepsis patients |
|
| |
|
|
| ||||
| TGF-β codon 10 C/T& codon25 G/C | CG | 19(76) | 72(80.9) | ||
| CC | 2(8) | 1(1.1) | 3.6 | 0.18 | |
| TG | 4(16) | 16(18.0) | |||
| TNF-α-308 G/A &-238 G/A | GG | 21(92) | 86(96.7) | ||
| GA | 2(8) | 0(0) | 8.0 | 0.05 | |
| AG | 0(0) | 3(3.3) | |||
| IL2 -330 T/G & + 160 G/T | GG | 6(24) | 18(20.2) | ||
| TG | 19(76) | 65(73) | 1.8 | 0.76 | |
| GT | 0(0) | 1(1.1) | |||
| TT | 0(0) | 5(5.7) | |||
| IL4-1098 T/G, −590 C/T & -590 C/T | GCC | 0(0) | 2(2.2) | ||
| TCC | 20(80) | 70(78.6) | 0.57 | 0.99 | |
| TTT | 5(20) | 17(19.2) | |||
| IL6-174 G/C & + 565 A/G | GG | 24(96) | 86(96.6) | 0.50 | 0.63 |
| CG | 0(0) | 1(1.1) | |||
| GA | 1(4) | 2(2.3) | |||
| IL10 -1082 G/A, −819C/T &-592 C/A | GCC | 8(32) | 30(33.7) | ||
| ACC | 13(52) | 58(65.1) | 10.4 | 0.01 | |
| ATA | 4(16) | 1(1.2) | |||
Comparison of genotypic and allelic frequency in non-survivors and survivors patients
| Cytokine gene polymorphism | Genotype/Allele | Survivors | Non-survivors |
| OR (95 % CI) |
|---|---|---|---|---|---|
|
|
| ||||
|
|
| ||||
| IL-1β(−511) | CC | 34(44.1) | 9(24.4) | 1 | |
| CT | 27(35) | 20(54) | 0.03 | 2.7(1.0–7.1) | |
| TT | 16(20.9) | 8(21.6) | 1.8(0.61–5.8) | ||
| C | 95(83.3) | 38(51.3) | 0.13 | 1 | |
| T | 59(16.7) | 36(49.7) | 1.5(0.83–2.7) | ||
| IL-1R(pst I 1970) | CC | 29(37.6) | 9(24.3) | 1 | |
| CT | 41(53.2) | 17(45.9) | 0.02 | 1.3(0.52–3.4) | |
| TT | 7(9.0) | 11(29.8) | 5.0(1.5–16.9) | ||
| C | 99(64.2) | 35(47.3) | 0.01 | 1 | |
| T | 55(35.8) | 39(52.7) | 2.0(1.0–3.6) | ||
| IL-4R(+1902) | AA | 51(66.2) | 17(46) | 1 | |
| GA | 22(28.6) | 16(43) | 0.08 | 2.1(0.93–5.0) | |
| GG | 4(5.2) | 4(11) | 3(0.67–13.3) | ||
| A | 124(80.5) | 15(20.2) | 0.001 | 1 | |
| G | 30(19.5) | 59(79.8) | 16.2(7.7–34.7) | ||
| IL-12(−1188) | CC | 10(12.9) | 3(8.1) | 1 | |
| CA | 25(32.4) | 9(24.3) | 0.49 | 1.2(0.26–5.3) | |
| AA | 42(54.7) | 25(67.6) | 1.9(0.49–7.9) | ||
| C | 45(29.2) | 47(20.2) | 0.001 | 1 | |
| A | 109(70.8) | 27(79.8) | 0.23(0.12–0.44) | ||
| TGF-β(codon25) | CC | 61(79.2) | 26(70.27) | 1 | |
| CG | 14(18.2) | 8(21.62) | 0.04 | 1.3(0.50–3.6) | |
| GG | 2(2.6) | 3(8.1) | 3.5(0.55–22.3) | ||
| C | 136(88.3) | 60(81.1) | 0.14 | 1 | |
| G | 18(11.7) | 14(18.9) | 0.56(0.24–1.3) |
Distribution of genotypes in non-survivors and survivors patients using multivariate logistic regression analysis
| Name of the cytokine gene with position | Genotype | Survivors | Non-survivors | Unadjusted odds ratio | Adjusted odds ratio | ||
|---|---|---|---|---|---|---|---|
| f (%) | f (%) | OR (95 % CI) |
| OR (95 % CI) |
| ||
|
|
| ||||||
| IL-1R(pst I 1970) | CC | 29(37.6) | 9(24.3) | 1 | 1 | ||
| CT | 41(53.2) | 17(45.9) | 1.3(0.52–3.4) | 0.54 | 0.9(0.06–14.8) | 0.99 | |
| TT | 7(9.0) | 11(29.8) | 5.0(1.5–16.9) | 0.08 | 19.9(0.6–577) | 0.08 | |
| IL4R(+1902) | AA | 51(66.2) | 17(46) | 1 | 1 | ||
| GA | 22(28.6) | 16(43) | 2.1(0.93–5.0) | 0.07 | 3.6(1.0–12.4) | 0.48 | |
| GG | 4(5.2) | 4(11) | 3(0.67–13.3) | 0.14 | 21.8(3.2–148) | 0.61 | |
| IL-1β(−511) | CC | 34(44.1) | 9(24.4) | 1 | 1 | ||
| CT | 27(35) | 20(54) | 2.7(1.0–7.1) | 0.03 | 9.8(0.75–128.2) | 0.08 | |
| TT | 16(20.9) | 8(21.6) | 1.8(0.61–5.8) | 0.26 | 3.2(0.09–114 | 0.51 | |
| TGF-β(codon25) | CC | 61(79.2) | 26(70.27) | 1 | 1 | ||
| CG | 14(18.2) | 8(21.62) | 1.3(0.50–3.6) | 0.55 | 1.7(0.50–6.4) | 0.37 | |
| GG | 2(2.6) | 3(8.1) | 3.5(0.55–22.3) | 0.18 | 15(1.5–141) | 0.01 | |
Adjusted odds ratio at 95 % CI of genotypes with ISS and SOFA score
Distribution of Haplotype frequency in non-survivors and survivors patients
| Cytokine gene | Haplotypes | Distribution of haplotype in survivors and non-survivors patients | |||
|---|---|---|---|---|---|
| Polymorphism | Survivors | Non-survivors |
|
| |
|
|
| ||||
| TGF-β codon 10 C/T& codon25 G/C | CG | 65(84.4) | 26(70.2) | ||
| CC | 0(0) | 3(8.1) | 7.3 | 0.02 | |
| TG | 12(15.6) | 8(21.7) | |||
| TNF-α-308 G/A &-238 G/A | GG | 75(97.4) | 34(91.9) | ||
| GA | 1(1.3) | 1(2.7) | 1.9 | 0.22 | |
| AG | 1(1.3) | 2(5.4) | |||
| IL2 -330 T/G & + 160 G/T | GG | 18(23.3) | 6(16.2) | ||
| TG | 55(71.4) | 19(78.4) | 3.2 | 0.37 | |
| GT | 0(0) | 1(2.7) | |||
| TT | 4(5.2) | 1(2.7) | |||
| IL4-1098 T/G, −590 C/T & -590 C/T | GCC | 1(1.3) | 1(2.7) | ||
| TCC | 64(83.1) | 26(70.3) | 2.5 | 0.25 | |
| TTT | 12(15.6) | 10(27) | |||
| IL6-174 G/C & + 565 A/G | GG | 74(96.1) | 36(97.3) | ||
| CG | 1(1.3) | 0(0) | 0.48 | 0.99 | |
| GA | 2(2.6) | 1(2.7) | |||
| IL10 -1082 G/A, −819C/T &-592 C/A | GCC | 26(33.7) | 12(32.4) | ||
| ACC | 47(61.1) | 24(64.8) | 0.42 | 0.99 | |
| ATA | 4(5.2) | 1(2.8) | |||
Showing the serum levels of IL-1α, TNF-α and IL-10 in healthy controls and patients
| Genotype | Healthy controls | Non-sepsis | Sepsis |
| ||||
|---|---|---|---|---|---|---|---|---|
| Percent | pg/ml | Percent | pg/ml | Percent | pg/ml | |||
| IL-1α(−889) | CC | 48.5 | 5.4 ± 2.8 | 50.5 | 7.2 ± 2.6 | 84 | 18.6 ± 7.8 | NS, pb<0.05, pc<0.05 |
| CT | 38.6 | 5.7 ± 1.9 | 35.9 | 8.3 ± 3.1 | 12 | 21.5 ± 8.7 | NS, pb<0.05, pc<0.05 | |
| TT | 12.9 | 3.7 ± 2.7 | 13.6 | 6.7 ± 2.7 | 4 | 16.2 ± 9.2 | pa<0.05, pb<0.05, pc<0.05 | |
| TNF-α(−308) | AA | 2.8 | 25.7 ± 18.6 | 3.3 | 37.5 ± 16.8 | 8 | 57.6 ± 18.7 | pa<0.05, pb<0.001, pc<0.001 |
| GA | 17.2 | 15.4 ± 9.7 | 19.1 | 34.6 ± 13.5 | 4 | 54.7 ± 19.6 | pa<0.001, pb<0.001, pc<0.001 | |
| GG | 80 | 11.2 ± 7.2 | 77.6 | 32.5 ± 12.7 | 88 | 51.2 ± 16.3 | pa<0.05, pb<0.001, pc<0.0001 | |
| TNF-α(−238) | GG | 90 | 27.6 ± 16.7 | 87.7 | 35.2 ± 14.6 | 76 | 40.6 ± 23.5 | pa<0.05, pb<0.001, pc<0.0001 |
| GA | 8.5 | 18.5 ± 12.3 | 11.2 | 30.5 ± 13.4 | 16 | 62.8 ± 18.6 | pa<0.05, pb<0.001, pc<0.0001 | |
| AA | 1.5 | 14.8 ± 7.8 | 1.1 | 32.4 ± 12.7 | 8 | 38.8 ± 14.8 | pa<0.05, pb<0.001, pc<0.0001 | |
| IL-10(−1082) | GG | 7.1 | 11.6 ± 4.7 | 5.7 | 21.6 ± 13.5 | 16 | 84.5 ± 37.5 | pa<0.01, pb<0.0001, pc<0.0001 |
| GA | 18.6 | 14.7 ± 5.2 | 37 | 22.5 ± 15.6 | 8 | 74.6 ± 26.3 | pa<0.01, pb<0.001, pc<0.0001 | |
| AA | 74.3 | 9.2 ± 4.5 | 57.3 | 16.7 ± 11.2 | 76 | 67.8 ± 21.4 | pa<0.01, pb<0.001, pc<0.0001 | |
p value (p < 0.05) considered as significant. It is calculated by two tailed Mann–Whitney, pa(healthy controls vs. non-sepsis),pb(healthy controls vs sepsis) and pc(sepsis vs. non-sepsis)